These days, we’re not surprised to open the paper and see another headline about the latest Epi-pen, Martin Shkreli, or yet another new drug with an exorbitant price tag that has no basis in reality. Since Sovaldi, a pill to treat Hepatitis C, hit the market at a price point of $1,000 (never mind that you could purchase it for $4 per pill in India), it has become acceptable for mass market therapies to suddenly become very expensive — often to the tune of $100,000 per therapy per patient per year.